Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis
2023-504786-23-00Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2024
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 2 trial of vx-522 in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability of VX-522. Started Jun 2024; status: completed.
02
Drugs
vx-522
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2023-504786-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504786-23-00.